2026-08-18 · By WeightFAQ Staff

Mazdutide for Weight Loss: Evidence and Safety

Mazdutide (development code IBI362) is a medicine that activates both the GLP-1 and glucagon receptors. China’s National Medical Products Administration approved mazdutide in June 2025 for chronic weight management in adults with overweight or obesity. The approval applies to China; it does not establish approval or availability in another country. Discuss any treatment decision with a qualified clinician and check the regulator’s current information where you live.

What the GLORY-1 trial found

GLORY-1 randomly assigned 610 Chinese adults with obesity, or overweight with a weight-related condition, to once-weekly mazdutide 4 mg, mazdutide 6 mg, or placebo. At 48 weeks, average weight change was −11.00% with 4 mg, −14.01% with 6 mg, and +0.30% with placebo. At 32 weeks, 73.9%, 82.0%, and 10.5%, respectively, had lost at least 5% of their starting weight. These are group averages and do not predict an individual’s outcome. The two main outcomes were assessed at 32 weeks; the 48-week numbers are later results from the same trial.

Participants received study treatment in a controlled trial. The results do not establish an identical effect in every population or predict weight maintenance after treatment ends. Benefits and adverse effects both matter when considering a medicine.

A separate higher-dose study

GLORY-2 was a different randomized trial, not the 9 mg arm of GLORY-1. It studied Chinese adults with obesity, some of whom had type 2 diabetes, alongside a reduced-calorie diet and increased activity. At 60 weeks, average weight change was −16.65% with 9 mg mazdutide versus −1.50% with placebo. These results cannot establish that a particular dose is appropriate for an individual; dosing and availability depend on local approval and clinical assessment.

What about diabetes?

A separate phase 3 trial studied Chinese adults with type 2 diabetes inadequately controlled with diet and exercise. At 24 weeks, average HbA1c changes were −1.57 percentage points with 4 mg and −2.15 points with 6 mg, compared with −0.14 points with placebo. Weight also decreased on average. This study does not mean the weight-management approval automatically applies to diabetes or to other countries. A clinician can explain which treatments are approved and suitable locally.

Side effects and safety

Gastrointestinal problems are important to consider. In GLORY-2, vomiting, nausea and diarrhea were more common with mazdutide than placebo; most reported events were mild or moderate. Treatment discontinuation because of adverse events occurred in 2.9% of the mazdutide group and 0% of the placebo group. GLORY-1 likewise reported gastrointestinal effects as the most frequent adverse events. These findings do not rule out uncommon or longer-term risks.

Tell a clinician about your medical history, medicines, symptoms and treatment goals. Seek their advice before starting, stopping or changing a medication. Avoid relying on unverified products marketed online: their contents, quality and storage may be uncertain.

Comparing treatments

Mazdutide acts on GLP-1 and glucagon receptors; tirzepatide acts on GLP-1 and GIP receptors. Results from separate trials have different participants, doses, study lengths and methods. They should not be treated as a head-to-head ranking or as an individual prediction. For an overview of approved treatment choices and practical questions to discuss with a clinician, see prescription weight-loss medications and the GLP-1 overview.

Questions to ask a clinician

• Is a weight-management medicine appropriate for my health and goals?
• Which options are approved and available where I live?
• What side effects and interactions should I watch for, and when should I seek help?
• How will we assess benefit, affordability and ongoing treatment?

Browse evergreen Weight Loss Guides →